Predictors of recurrent ischemic optic neuropathy in giant cell arteritis

Journal of Neuro-Ophthalmology

Volumn 25, Issue 1, 2005, Pages 14-17

  Chan, Colin C K ^a,b   Paine, Mark ^a,b   O'Day, Justin ^a,b  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b MBBS(HONS)   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

ACUTE PHASE RESPONSE; ADULT; AGE DISTRIBUTION; AGED; AUSTRALIA; CORTICOSTEROID THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; GIANT CELL ARTERITIS; HUMAN; ISCHEMIC OPTIC NEUROPATHY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT; SYMPTOMATOLOGY; VISUAL ACUITY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEADACHE; HUMANS; MALE; OPTIC NEUROPATHY, ISCHEMIC; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; TEMPORAL ARTERITIS;

EID: 14844361980     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200503000-00004     Document Type: Review

References (3)

1. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239-59.
2. Liu GT, Glaser JS, Schatz NJ et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology. 1994;101:1779-85.
3. Kim N, Trobe JD, Flint A, et al. Late ipsilateral recurrence of ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2003;23: 122-6.